These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20061646)

  • 1. Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia.
    Sonnen JA; Montine KS; Quinn JF; Breitner JC; Montine TJ
    J Alzheimers Dis; 2010; 19(1):301-9. PubMed ID: 20061646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for cognitive impairment and dementia in elderly people.
    Sonnen JA; Montine KS; Quinn JF; Kaye JA; Breitner JC; Montine TJ
    Lancet Neurol; 2008 Aug; 7(8):704-14. PubMed ID: 18635019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.
    Gonzalez-Cuyar LF; Sonnen JA; Montine KS; Keene CD; Montine TJ
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):455-63. PubMed ID: 21725901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
    Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.
    Hu WT; Chen-Plotkin A; Arnold SE; Grossman M; Clark CM; Shaw LM; Pickering E; Kuhn M; Chen Y; McCluskey L; Elman L; Karlawish J; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Acta Neuropathol; 2010 Jun; 119(6):669-78. PubMed ID: 20232070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
    Mitchell AJ; Monge-Argilés JA; Sánchez-Paya J
    Pract Neurol; 2010 Aug; 10(4):202-7. PubMed ID: 20647526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
    Marksteiner J; Hinterhuber H; Humpel C
    Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting.
    Lanari A; Parnetti L
    ScientificWorldJournal; 2009 Sep; 9():961-6. PubMed ID: 19768352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
    Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease.
    Montine TJ; Quinn JF; Montine KS; Kaye JA; Breitner JC
    J Alzheimers Dis; 2005 Mar; 8(4):359-67. PubMed ID: 16556967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.
    Parnetti L; Lanari A; Saggese E; Spaccatini C; Gallai V
    Neurol Sci; 2003 Oct; 24(3):199-200. PubMed ID: 14598086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
    Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
    J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
    Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population.
    Bertens D; Tijms BM; Scheltens P; Teunissen CE; Visser PJ
    Alzheimers Res Ther; 2017 Feb; 9(1):8. PubMed ID: 28193256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
    Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.